Carbamazepine Treatment for Cocaine Dependence - 5
Information source: University of Pennsylvania
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine-Related Disorders
Intervention: Carbamazepine (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: University of Pennsylvania Official(s) and/or principal investigator(s): James Cornish, M.D., Principal Investigator, Affiliation: University of Pennsylvania
Summary
The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine
dependence.
Clinical Details
Official title: Carbamazepine Treatment for Cocaine Dependence
Study design: Primary Purpose: Treatment
Eligibility
Minimum age: 21 Years.
Maximum age: 51 Years.
Gender(s): Both.
Criteria:
Please contact site for information.
Locations and Contacts
University of Pennsylvania, Philadelphia, Pennsylvania 19104 6178, United States
Additional Information
Related publications: Cornish JW, Maany I, Fudala PJ, Neal S, Poole SA, Volpicelli P, O'Brien CP. Carbamazepine treatment for cocaine dependence. Drug Alcohol Depend. 1995 Jun;38(3):221-7.
Starting date: January 1991
Last updated: May 26, 2015
|